Yong Ben
Known title: Chief Med & Dev OfficerCIK: 0001967669
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
BBOT reports inducement grants under Nasdaq Rule 5635(c)(4). BridgeBio Oncology Therapeutics announced that it has reported inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4). The disclosure confirms the company’s compliance with regulatory reporting requirements for incentive arrangements. While the announcement does not provide details on the size of the grants, it highlights ongoing governance practices.
Transaction History
| CRBP | ▼ Sell | Open Market | 2,000 | $16K | 9/14/2026 | View on chart |
| BBOT | ▼ Sell | Tax Withholding | 1,047 | $8K | 7/1/2026 | View on chart |
| CRBP | ▲ Buy | Grant | 3,800 | $0 | 5/19/2026 | View on chart |
| BBOT | ▼ Sell | Tax Withholding | 1,047 | $9K | 4/1/2026 | View on chart |
| BBOT | ▲ Buy | Grant | 46,670 | $0 | 3/10/2026 | View on chart |
| CRBP | ▲ Buy | Grant | 4,800 | $0 | 5/30/2025 | View on chart |
| CRBP | ▲ Buy | Grant | 2,783 | $0 | 5/30/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Corbus Doses First Patient in CRB-701 TEMPO-1 Study
Corbus Pharmaceuticals announced that the first patient has been dosed in the TEMPO-1 registrational study for CRB-701. This clinical trial focuses on patients with second-line or later oropharyngeal cancer. The update marks a significant step in the development timeline for the company's lead asset.
Corbus Doses First Patient in CRB-701 TEMPO-1 Study. Corbus Pharmaceuticals announced that the first patient has been dosed in the TEMPO-1 registrational study for CRB-701. This clinical trial focuses on patients with second-line or later oropharyngeal cancer. The update marks a significant step in the development timeline for the company's lead asset.